Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359657 · ClinicalTrials.gov registry record · Phase 1
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01359657 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants.
The verdict
NCT01359657, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in subjects with relapsed or refractory multiple myeloma.
Interventions
- BIOLOGICAL Bortezomib
- BIOLOGICAL Anti-CXCR4 (BMS-936564)
- BIOLOGICAL Lenalidomide
- BIOLOGICAL Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359657
The ClinicalTrials.gov registry entry for NCT01359657 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bortezomib is the first listed.
NCT01359657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359657 about?
NCT01359657 is a clinical study titled "Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma". The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in sub...
What is the current status of trial NCT01359657?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2011-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01359657?
The interventions under investigation include: Bortezomib (BIOLOGICAL), Anti-CXCR4 (BMS-936564) (BIOLOGICAL), Lenalidomide (BIOLOGICAL), Dexamethasone (BIOLOGICAL).
Who is sponsoring clinical trial NCT01359657?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.